-
1
-
-
84855688769
-
A systems biology approach identifies SART1 as a novel determinant of both 5-fluorouracil and SN38 drug resistance in colorectal cancer
-
Allen W.L., Stevenson L., Coyle V.M., Jithesh P.V., Proutski I., Carson G., Gordon M.A., Lenz H.J., Van Schaeybroeck S., Longley D.B., Johnston P.G. A systems biology approach identifies SART1 as a novel determinant of both 5-fluorouracil and SN38 drug resistance in colorectal cancer. Mol. Cancer Ther. 2012, 11:119-131.
-
(2012)
Mol. Cancer Ther.
, vol.11
, pp. 119-131
-
-
Allen, W.L.1
Stevenson, L.2
Coyle, V.M.3
Jithesh, P.V.4
Proutski, I.5
Carson, G.6
Gordon, M.A.7
Lenz, H.J.8
Van Schaeybroeck, S.9
Longley, D.B.10
Johnston, P.G.11
-
2
-
-
34547749466
-
C-Met ectodomain shedding rate correlates with malignant potential
-
Athauda G., Giubellino A., Coleman J.A., Horak C., Steeg P.S., Lee M.J., Trepel J., Wimberly J., Sun J., Coxon A., et al. c-Met ectodomain shedding rate correlates with malignant potential. Clin. Cancer Res. 2006, 12:4154-4162.
-
(2006)
Clin. Cancer Res.
, vol.12
, pp. 4154-4162
-
-
Athauda, G.1
Giubellino, A.2
Coleman, J.A.3
Horak, C.4
Steeg, P.S.5
Lee, M.J.6
Trepel, J.7
Wimberly, J.8
Sun, J.9
Coxon, A.10
-
3
-
-
80052187354
-
STK33 kinase activity is nonessential in KRAS-dependent cancer cells
-
Babij C., Zhang Y., Kurzeja R.J., Munzli A., Shehabeldin A., Fernando M., Quon K., Kassner P.D., Ruefli-Brasse A.A., Watson V.J., et al. STK33 kinase activity is nonessential in KRAS-dependent cancer cells. Cancer Res. 2011, 71:5818-5826.
-
(2011)
Cancer Res.
, vol.71
, pp. 5818-5826
-
-
Babij, C.1
Zhang, Y.2
Kurzeja, R.J.3
Munzli, A.4
Shehabeldin, A.5
Fernando, M.6
Quon, K.7
Kassner, P.D.8
Ruefli-Brasse, A.A.9
Watson, V.J.10
-
4
-
-
70449091786
-
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
-
Barbie D.A., Tamayo P., Boehm J.S., Kim S.Y., Moody S.E., Dunn I.F., Schinzel A.C., Sandy P., Meylan E., Scholl C., et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009, 462:108-112.
-
(2009)
Nature
, vol.462
, pp. 108-112
-
-
Barbie, D.A.1
Tamayo, P.2
Boehm, J.S.3
Kim, S.Y.4
Moody, S.E.5
Dunn, I.F.6
Schinzel, A.C.7
Sandy, P.8
Meylan, E.9
Scholl, C.10
-
5
-
-
0033583220
-
C-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function
-
Biscardi J.S., Maa M.C., Tice D.A., Cox M.E., Leu T.H., Parsons S.J. c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J.Biol. Chem. 1999, 274:8335-8343.
-
(1999)
J.Biol. Chem.
, vol.274
, pp. 8335-8343
-
-
Biscardi, J.S.1
Maa, M.C.2
Tice, D.A.3
Cox, M.E.4
Leu, T.H.5
Parsons, S.J.6
-
6
-
-
63649150787
-
A genomic strategy to elucidate modules of oncogenic pathway signaling networks
-
Chang J.T., Carvalho C., Mori S., Bild A.H., Gatza M.L., Wang Q., Lucas J.E., Potti A., Febbo P.G., West M., Nevins J.R. A genomic strategy to elucidate modules of oncogenic pathway signaling networks. Mol. Cell 2009, 34:104-114.
-
(2009)
Mol. Cell
, vol.34
, pp. 104-114
-
-
Chang, J.T.1
Carvalho, C.2
Mori, S.3
Bild, A.H.4
Gatza, M.L.5
Wang, Q.6
Lucas, J.E.7
Potti, A.8
Febbo, P.G.9
West, M.10
Nevins, J.R.11
-
7
-
-
0021118703
-
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors
-
Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22:27-55.
-
(1984)
Adv. Enzyme Regul.
, vol.22
, pp. 27-55
-
-
Chou, T.C.1
Talalay, P.2
-
8
-
-
0021848596
-
Antibodies specific for amino acid 12 of the ras oncogene product inhibit GTP binding
-
Clark R., Wong G., Arnheim N., Nitecki D., McCormick F. Antibodies specific for amino acid 12 of the ras oncogene product inhibit GTP binding. Proc. Natl. Acad. Sci. USA 1985, 82:5280-5284.
-
(1985)
Proc. Natl. Acad. Sci. USA
, vol.82
, pp. 5280-5284
-
-
Clark, R.1
Wong, G.2
Arnheim, N.3
Nitecki, D.4
McCormick, F.5
-
9
-
-
44449151030
-
Drug development of MET inhibitors: targeting oncogene addiction and expedience
-
Comoglio P.M., Giordano S., Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat. Rev. Drug Discov. 2008, 7:504-516.
-
(2008)
Nat. Rev. Drug Discov.
, vol.7
, pp. 504-516
-
-
Comoglio, P.M.1
Giordano, S.2
Trusolino, L.3
-
10
-
-
22044437986
-
Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth
-
Corvinus F.M., Orth C., Moriggl R., Tsareva S.A., Wagner S., Pfitzner E.B., Baus D., Kaufmann R., Huber L.A., Zatloukal K., et al. Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia 2005, 7:545-555.
-
(2005)
Neoplasia
, vol.7
, pp. 545-555
-
-
Corvinus, F.M.1
Orth, C.2
Moriggl, R.3
Tsareva, S.A.4
Wagner, S.5
Pfitzner, E.B.6
Baus, D.7
Kaufmann, R.8
Huber, L.A.9
Zatloukal, K.10
-
11
-
-
0035799531
-
Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells
-
Garcia R., Bowman T.L., Niu G., Yu H., Minton S., Muro-Cacho C.A., Cox C.E., Falcone R., Fairclough R., Parsons S., et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 2001, 20:2499-2513.
-
(2001)
Oncogene
, vol.20
, pp. 2499-2513
-
-
Garcia, R.1
Bowman, T.L.2
Niu, G.3
Yu, H.4
Minton, S.5
Muro-Cacho, C.A.6
Cox, C.E.7
Falcone, R.8
Fairclough, R.9
Parsons, S.10
-
12
-
-
58649108302
-
IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer
-
Grivennikov S., Karin E., Terzic J., Mucida D., Yu G.Y., Vallabhapurapu S., Scheller J., Rose-John S., Cheroutre H., Eckmann L., Karin M. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009, 15:103-113.
-
(2009)
Cancer Cell
, vol.15
, pp. 103-113
-
-
Grivennikov, S.1
Karin, E.2
Terzic, J.3
Mucida, D.4
Yu, G.Y.5
Vallabhapurapu, S.6
Scheller, J.7
Rose-John, S.8
Cheroutre, H.9
Eckmann, L.10
Karin, M.11
-
13
-
-
26844556553
-
GPCR-induced migration of breast carcinoma cells depends on both EGFR signal transactivation and EGFR-independent pathways
-
Hart S., Fischer O.M., Prenzel N., Zwick-Wallasch E., Schneider M., Hennighausen L., Ullrich A. GPCR-induced migration of breast carcinoma cells depends on both EGFR signal transactivation and EGFR-independent pathways. Biol. Chem. 2005, 386:845-855.
-
(2005)
Biol. Chem.
, vol.386
, pp. 845-855
-
-
Hart, S.1
Fischer, O.M.2
Prenzel, N.3
Zwick-Wallasch, E.4
Schneider, M.5
Hennighausen, L.6
Ullrich, A.7
-
14
-
-
70949094349
-
The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors
-
Hedvat M., Huszar D., Herrmann A., Gozgit J.M., Schroeder A., Sheehy A., Buettner R., Proia D., Kowolik C.M., Xin H., et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 2009, 16:487-497.
-
(2009)
Cancer Cell
, vol.16
, pp. 487-497
-
-
Hedvat, M.1
Huszar, D.2
Herrmann, A.3
Gozgit, J.M.4
Schroeder, A.5
Sheehy, A.6
Buettner, R.7
Proia, D.8
Kowolik, C.M.9
Xin, H.10
-
15
-
-
40949135397
-
PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab
-
Jhawer M., Goel S., Wilson A.J., Montagna C., Ling Y.H., Byun D.S., Nasser S., Arango D., Shin J., Klampfer L., et al. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res. 2008, 68:1953-1961.
-
(2008)
Cancer Res.
, vol.68
, pp. 1953-1961
-
-
Jhawer, M.1
Goel, S.2
Wilson, A.J.3
Montagna, C.4
Ling, Y.H.5
Byun, D.S.6
Nasser, S.7
Arango, D.8
Shin, J.9
Klampfer, L.10
-
16
-
-
3142619403
-
The Sema domain of Met is necessary for receptor dimerization and activation
-
Kong-Beltran M., Stamos J., Wickramasinghe D. The Sema domain of Met is necessary for receptor dimerization and activation. Cancer Cell 2004, 6:75-84.
-
(2004)
Cancer Cell
, vol.6
, pp. 75-84
-
-
Kong-Beltran, M.1
Stamos, J.2
Wickramasinghe, D.3
-
17
-
-
77954238685
-
Chemotherapy-induced activation of ADAM-17: a novel mechanism of drug resistance in colorectal cancer
-
Kyula J.N., Van Schaeybroeck S., Doherty J., Fenning C.S., Longley D.B., Johnston P.G. Chemotherapy-induced activation of ADAM-17: a novel mechanism of drug resistance in colorectal cancer. Clin. Cancer Res. 2010, 16:3378-3389.
-
(2010)
Clin. Cancer Res.
, vol.16
, pp. 3378-3389
-
-
Kyula, J.N.1
Van Schaeybroeck, S.2
Doherty, J.3
Fenning, C.S.4
Longley, D.B.5
Johnston, P.G.6
-
18
-
-
79952654912
-
TACE/ADAM-17 phosphorylation by PKC-epsilon mediates premalignant changes in tobacco smoke-exposed lung cells
-
Lemjabbar-Alaoui H., Sidhu S.S., Mengistab A., Gallup M., Basbaum C. TACE/ADAM-17 phosphorylation by PKC-epsilon mediates premalignant changes in tobacco smoke-exposed lung cells. PLoS ONE 2011, 6:e17489.
-
(2011)
PLoS ONE
, vol.6
-
-
Lemjabbar-Alaoui, H.1
Sidhu, S.S.2
Mengistab, A.3
Gallup, M.4
Basbaum, C.5
-
19
-
-
79953240219
-
Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells
-
Little A.S., Balmanno K., Sale M.J., Newman S., Dry J.R., Hampson M., Edwards P.A., Smith P.D., Cook S.J. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. Sci. Signal. 2011, 4:ra17.
-
(2011)
Sci. Signal.
, vol.4
-
-
Little, A.S.1
Balmanno, K.2
Sale, M.J.3
Newman, S.4
Dry, J.R.5
Hampson, M.6
Edwards, P.A.7
Smith, P.D.8
Cook, S.J.9
-
20
-
-
66149091940
-
A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene
-
Luo J., Emanuele M.J., Li D., Creighton C.J., Schlabach M.R., Westbrook T.F., Wong K.K., Elledge S.J. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009, 137:835-848.
-
(2009)
Cell
, vol.137
, pp. 835-848
-
-
Luo, J.1
Emanuele, M.J.2
Li, D.3
Creighton, C.J.4
Schlabach, M.R.5
Westbrook, T.F.6
Wong, K.K.7
Elledge, S.J.8
-
21
-
-
79959337678
-
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
-
MRC COIN Trial Investigators.
-
Maughan T.S., Adams R.A., Smith C.G., Meade A.M., Seymour M.T., Wilson R.H., Idziaszczyk S., Harris R., Fisher D., Kenny S.L., et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011, 377:2103-2114. MRC COIN Trial Investigators.
-
(2011)
Lancet
, vol.377
, pp. 2103-2114
-
-
Maughan, T.S.1
Adams, R.A.2
Smith, C.G.3
Meade, A.M.4
Seymour, M.T.5
Wilson, R.H.6
Idziaszczyk, S.7
Harris, R.8
Fisher, D.9
Kenny, S.L.10
-
22
-
-
39749085844
-
TACE/ADAM-17: a component of the epidermal growth factor receptor axis and a promising therapeutic target in colorectal cancer
-
Merchant N.B., Voskresensky I., Rogers C.M., Lafleur B., Dempsey P.J., Graves-Deal R., Revetta F., Foutch A.C., Rothenberg M.L., Washington M.K., Coffey R.J. TACE/ADAM-17: a component of the epidermal growth factor receptor axis and a promising therapeutic target in colorectal cancer. Clin. Cancer Res. 2008, 14:1182-1191.
-
(2008)
Clin. Cancer Res.
, vol.14
, pp. 1182-1191
-
-
Merchant, N.B.1
Voskresensky, I.2
Rogers, C.M.3
Lafleur, B.4
Dempsey, P.J.5
Graves-Deal, R.6
Revetta, F.7
Foutch, A.C.8
Rothenberg, M.L.9
Washington, M.K.10
Coffey, R.J.11
-
23
-
-
3142512610
-
Targeting the tumor and its microenvironment by a dual-function decoy Met receptor
-
Michieli P., Mazzone M., Basilico C., Cavassa S., Sottile A., Naldini L., Comoglio P.M. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 2004, 6:61-73.
-
(2004)
Cancer Cell
, vol.6
, pp. 61-73
-
-
Michieli, P.1
Mazzone, M.2
Basilico, C.3
Cavassa, S.4
Sottile, A.5
Naldini, L.6
Comoglio, P.M.7
-
24
-
-
0037112367
-
Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells
-
Mora L.B., Buettner R., Seigne J., Diaz J., Ahmad N., Garcia R., Bowman T., Falcone R., Fairclough R., Cantor A., et al. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res. 2002, 62:6659-6666.
-
(2002)
Cancer Res.
, vol.62
, pp. 6659-6666
-
-
Mora, L.B.1
Buettner, R.2
Seigne, J.3
Diaz, J.4
Ahmad, N.5
Garcia, R.6
Bowman, T.7
Falcone, R.8
Fairclough, R.9
Cantor, A.10
-
25
-
-
79952715805
-
STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers
-
Morikawa T., Baba Y., Yamauchi M., Kuchiba A., Nosho K., Shima K., Tanaka N., Huttenhower C., Frank D.A., Fuchs C.S., Ogino S. STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers. Clin. Cancer Res. 2011, 17:1452-1462.
-
(2011)
Clin. Cancer Res.
, vol.17
, pp. 1452-1462
-
-
Morikawa, T.1
Baba, Y.2
Yamauchi, M.3
Kuchiba, A.4
Nosho, K.5
Shima, K.6
Tanaka, N.7
Huttenhower, C.8
Frank, D.A.9
Fuchs, C.S.10
Ogino, S.11
-
26
-
-
56749133149
-
The ADAMs: signalling scissors in the tumour microenvironment
-
Murphy G. The ADAMs: signalling scissors in the tumour microenvironment. Nat. Rev. Cancer 2008, 8:929-941.
-
(2008)
Nat. Rev. Cancer
, vol.8
, pp. 929-941
-
-
Murphy, G.1
-
27
-
-
0034108378
-
Prognostic role of K-ras in patients with progressive colon cancer who received treatment with Marimastat (BB2516)
-
Nemunaitis J., Cox J., Hays S., Meyer W., Kebart R., Ognoskie N., Courtney A., Yu Y., Rasmussen H., Tong A. Prognostic role of K-ras in patients with progressive colon cancer who received treatment with Marimastat (BB2516). Cancer Invest. 2000, 18:185-190.
-
(2000)
Cancer Invest.
, vol.18
, pp. 185-190
-
-
Nemunaitis, J.1
Cox, J.2
Hays, S.3
Meyer, W.4
Kebart, R.5
Ognoskie, N.6
Courtney, A.7
Yu, Y.8
Rasmussen, H.9
Tong, A.10
-
28
-
-
84863230465
-
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
-
Prahallad A., Sun C., Huang S., Di Nicolantonio F., Salazar R., Zecchin D., Beijersbergen R.L., Bardelli A., Bernards R. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012, 483:100-103.
-
(2012)
Nature
, vol.483
, pp. 100-103
-
-
Prahallad, A.1
Sun, C.2
Huang, S.3
Di Nicolantonio, F.4
Salazar, R.5
Zecchin, D.6
Beijersbergen, R.L.7
Bardelli, A.8
Bernards, R.9
-
29
-
-
65849111219
-
Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells
-
Scholl C., Fröhling S., Dunn I.F., Schinzel A.C., Barbie D.A., Kim S.Y., Silver S.J., Tamayo P., Wadlow R.C., Ramaswamy S., et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 2009, 137:821-834.
-
(2009)
Cell
, vol.137
, pp. 821-834
-
-
Scholl, C.1
Fröhling, S.2
Dunn, I.F.3
Schinzel, A.C.4
Barbie, D.A.5
Kim, S.Y.6
Silver, S.J.7
Tamayo, P.8
Wadlow, R.C.9
Ramaswamy, S.10
-
30
-
-
0037224740
-
The ADAMs family of metalloproteases: multidomain proteins with multiple functions
-
Seals D.F., Courtneidge S.A. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev. 2003, 17:7-30.
-
(2003)
Genes Dev.
, vol.17
, pp. 7-30
-
-
Seals, D.F.1
Courtneidge, S.A.2
-
31
-
-
79551709762
-
Distinct interactions between c-Src and c-Met in mediating resistance to c-Src inhibition in head and neck cancer
-
Sen B., Peng S., Saigal B., Williams M.D., Johnson F.M. Distinct interactions between c-Src and c-Met in mediating resistance to c-Src inhibition in head and neck cancer. Clin. Cancer Res. 2011, 17:514-524.
-
(2011)
Clin. Cancer Res.
, vol.17
, pp. 514-524
-
-
Sen, B.1
Peng, S.2
Saigal, B.3
Williams, M.D.4
Johnson, F.M.5
-
32
-
-
0027905014
-
Altered growth of human colon cancer cell lines disrupted at activated Ki-ras
-
Shirasawa S., Furuse M., Yokoyama N., Sasazuki T. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 1993, 260:85-88.
-
(1993)
Science
, vol.260
, pp. 85-88
-
-
Shirasawa, S.1
Furuse, M.2
Yokoyama, N.3
Sasazuki, T.4
-
33
-
-
84866932861
-
Identification of galanin and its receptor GalR1 as novel determinants of resistance to chemotherapy and potential biomarkers in colorectal cancer
-
Stevenson L., Allen W.L., Turkington R., Jithesh P.V., Proutski I., Stewart G., Lenz H.J., Van Schaeybroeck S., Longley D.B., Johnston P.G. Identification of galanin and its receptor GalR1 as novel determinants of resistance to chemotherapy and potential biomarkers in colorectal cancer. Clin. Cancer Res. 2012, 18:5412-5426.
-
(2012)
Clin. Cancer Res.
, vol.18
, pp. 5412-5426
-
-
Stevenson, L.1
Allen, W.L.2
Turkington, R.3
Jithesh, P.V.4
Proutski, I.5
Stewart, G.6
Lenz, H.J.7
Van Schaeybroeck, S.8
Longley, D.B.9
Johnston, P.G.10
-
34
-
-
0034795339
-
Use of isogenic human cancer cells for high-throughput screening and drug discovery
-
Torrance C.J., Agrawal V., Vogelstein B., Kinzler K.W. Use of isogenic human cancer cells for high-throughput screening and drug discovery. Nat. Biotechnol. 2001, 19:940-945.
-
(2001)
Nat. Biotechnol.
, vol.19
, pp. 940-945
-
-
Torrance, C.J.1
Agrawal, V.2
Vogelstein, B.3
Kinzler, K.W.4
-
35
-
-
79956298812
-
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status
-
Van Cutsem E., Köhne C.H., Láng I., Folprecht G., Nowacki M.P., Cascinu S., Shchepotin I., Maurel J., Cunningham D., Tejpar S., et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J.Clin. Oncol. 2011, 29:2011-2019.
-
(2011)
J.Clin. Oncol.
, vol.29
, pp. 2011-2019
-
-
Van Cutsem, E.1
Köhne, C.H.2
Láng, I.3
Folprecht, G.4
Nowacki, M.P.5
Cascinu, S.6
Shchepotin, I.7
Maurel, J.8
Cunningham, D.9
Tejpar, S.10
-
36
-
-
54249144029
-
Src and ADAM-17-mediated shedding of transforming growth factor-alpha is a mechanism of acute resistance to TRAIL
-
Van Schaeybroeck S., Kelly D.M., Kyula J., Stokesberry S., Fennell D.A., Johnston P.G., Longley D.B. Src and ADAM-17-mediated shedding of transforming growth factor-alpha is a mechanism of acute resistance to TRAIL. Cancer Res. 2008, 68:8312-8321.
-
(2008)
Cancer Res.
, vol.68
, pp. 8312-8321
-
-
Van Schaeybroeck, S.1
Kelly, D.M.2
Kyula, J.3
Stokesberry, S.4
Fennell, D.A.5
Johnston, P.G.6
Longley, D.B.7
-
37
-
-
79551544279
-
Oncogenic Kras promotes chemotherapy-induced growth factor shedding via ADAM17
-
Van Schaeybroeck S., Kyula J.N., Fenton A., Fenning C.S., Sasazuki T., Shirasawa S., Longley D.B., Johnston P.G. Oncogenic Kras promotes chemotherapy-induced growth factor shedding via ADAM17. Cancer Res. 2011, 71:1071-1080.
-
(2011)
Cancer Res.
, vol.71
, pp. 1071-1080
-
-
Van Schaeybroeck, S.1
Kyula, J.N.2
Fenton, A.3
Fenning, C.S.4
Sasazuki, T.5
Shirasawa, S.6
Longley, D.B.7
Johnston, P.G.8
-
38
-
-
41249099841
-
Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera
-
Wernig G., Kharas M.G., Okabe R., Moore S.A., Leeman D.S., Cullen D.E., Gozo M., McDowell E.P., Levine R.L., Doukas J., et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 2008, 13:311-320.
-
(2008)
Cancer Cell
, vol.13
, pp. 311-320
-
-
Wernig, G.1
Kharas, M.G.2
Okabe, R.3
Moore, S.A.4
Leeman, D.S.5
Cullen, D.E.6
Gozo, M.7
McDowell, E.P.8
Levine, R.L.9
Doukas, J.10
-
39
-
-
33745791118
-
Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer
-
Zhou B.B., Peyton M., He B., Liu C., Girard L., Caudler E., Lo Y., Baribaud F., Mikami I., Reguart N., et al. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell 2006, 10:39-50.
-
(2006)
Cancer Cell
, vol.10
, pp. 39-50
-
-
Zhou, B.B.1
Peyton, M.2
He, B.3
Liu, C.4
Girard, L.5
Caudler, E.6
Lo, Y.7
Baribaud, F.8
Mikami, I.9
Reguart, N.10
|